Partners Capital Investment Group LLP lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 208,296 shares of the company’s stock after selling 7,418 shares during the quarter. Johnson & Johnson makes up about 2.9% of Partners Capital Investment Group LLP’s portfolio, making the stock its 13th biggest holding. Partners Capital Investment Group LLP’s holdings in Johnson & Johnson were worth $29,011,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Crewe Advisors LLC grew its stake in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Evolution Wealth Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. Permanens Capital L.P. grew its stake in Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. Thor Advisors LLC purchased a new position in Johnson & Johnson in the first quarter valued at about $69,000. Finally, Personal Wealth Partners purchased a new position in Johnson & Johnson in the second quarter valued at about $73,000. 72.12% of the stock is currently owned by institutional investors.

Shares of JNJ traded down $0.32 during trading hours on Friday, hitting $130.11. 1,656,706 shares of the company were exchanged, compared to its average volume of 7,701,360. The company has a market cap of $341.90 billion, a PE ratio of 15.91, a PEG ratio of 2.19 and a beta of 0.68. The firm’s 50 day moving average is $130.11 and its 200-day moving average is $135.97. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.10 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of research analysts have commented on JNJ shares. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Bank of America reiterated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a research note on Thursday, July 18th. Morgan Stanley reiterated an “equal weight” rating and set a $145.00 price target on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Finally, Barclays initiated coverage on Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 price target for the company. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Trade War

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.